300558 贝达药业
已收盘 12-20 15:00:00
资讯
新帖
简况
贝达药业1类新药在美国获批上市，健康元1类新药获批临床，济民健康降价22%与美国RTI签署代工协议
谈医说药 · 12-19 23:25
贝达药业1类新药在美国获批上市，健康元1类新药获批临床，济民健康降价22%与美国RTI签署代工协议
贝达药业：控股子公司盐酸恩沙替尼胶囊获美国FDA批准上市
中国财富通 · 12-19 17:30
贝达药业：控股子公司盐酸恩沙替尼胶囊获美国FDA批准上市
贝达药业(300558.SZ)子公司Xcovery盐酸恩沙替尼胶囊获美国FDA批准上市
智通财经 · 12-19 11:53
贝达药业(300558.SZ)子公司Xcovery盐酸恩沙替尼胶囊获美国FDA批准上市
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押94.8万股，占总股本0.23%
证券之星 · 12-18 21:23
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押94.8万股，占总股本0.23%
海通国际：给予贝达药业增持评级，目标价位69.08元
证券之星 · 12-16
海通国际：给予贝达药业增持评级，目标价位69.08元
贝达药业：公司一贯重视现金流管理，通过有效的预算管理、筹资管理等机制保持着健康的财务状况
证券之星 · 12-12
贝达药业：公司一贯重视现金流管理，通过有效的预算管理、筹资管理等机制保持着健康的财务状况
贝达药业(300558.SZ)向171名激励对象授予168.98万股限制性股票
智通财经 · 12-04
贝达药业(300558.SZ)向171名激励对象授予168.98万股限制性股票
11月29日贝达药业涨5.05%，圆信永丰兴源灵活配置混合A基金重仓该股
证券之星 · 11-29
11月29日贝达药业涨5.05%，圆信永丰兴源灵活配置混合A基金重仓该股
贝达药业涨5.05%，东海证券三周前给出“买入”评级
证券之星 · 11-29
贝达药业涨5.05%，东海证券三周前给出“买入”评级
贝达药业最新公告：甲磺酸贝福替尼一线治疗适应症纳入《国家医保目录》
证券之星 · 11-28
贝达药业最新公告：甲磺酸贝福替尼一线治疗适应症纳入《国家医保目录》
贝达药业(300558.SZ)甲磺酸贝福替尼一线治疗适应症纳入国家医保目录
智通财经 · 11-28
贝达药业(300558.SZ)甲磺酸贝福替尼一线治疗适应症纳入国家医保目录
A股创新药板块冲高，葫芦娃涨停，汇宇制药涨超7%，赛隆药业、贝达药业、艾力斯等跟涨。
美港电讯 · 11-26
A股创新药板块冲高，葫芦娃涨停，汇宇制药涨超7%，赛隆药业、贝达药业、艾力斯等跟涨。
来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投
活报告 · 11-25
来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投
翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐
瑞恩资本Ryanbe... · 11-25
翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐
贝达药业（300558）11月22日主力资金净卖出3327.72万元
证券之星 · 11-25
贝达药业（300558）11月22日主力资金净卖出3327.72万元
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊临床中心通过美国FDA现场核查
智通财经网 · 11-22
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊临床中心通过美国FDA现场核查
11月22日贝达药业跌7.04%，圆信永丰兴源灵活配置混合A基金重仓该股
证券之星 · 11-22
11月22日贝达药业跌7.04%，圆信永丰兴源灵活配置混合A基金重仓该股
贝达药业（300558）11月20日主力资金净买入2097.86万元
证券之星 · 11-21
贝达药业（300558）11月20日主力资金净买入2097.86万元
贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理
智通财经 · 11-20
贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理
贝达药业最新公告：BPI-452080片药物临床试验申请获得受理
证券之星 · 11-20
贝达药业最新公告：BPI-452080片药物临床试验申请获得受理
加载更多
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖（两次）、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":55.22,"timestamp":1734678204000,"preClose":54.5,"halted":0,"volume":4838700,"delay":0,"floatShares":417000000,"shares":418000000,"eps":1.0982,"marketStatus":"已收盘","marketStatusCode":5,"change":0.72,"latestTime":"12-20 15:00:00","open":54.7,"high":56.08,"low":54.52,"amount":268000000,"amplitude":0.0286,"askPrice":55.22,"askSize":28,"bidPrice":55.21,"bidSize":56,"shortable":0,"etf":0,"ttmEps":1.0982,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":54.5,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":59.95,"lowLimit":49.05,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":418485885,"pbRate":4.05,"roa":"--","roe":"7.64%","epsLYR":0.83,"committee":0.518182,"marketValue":23109000000,"floatMarketCap":23037000000,"peRate":50.282282,"changeRate":0.0132,"turnoverRate":0.0116,"status":0},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2492785177","title":"贝达药业1类新药在美国获批上市，健康元1类新药获批临床，济民健康降价22%与美国RTI签署代工协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492785177","media":"谈医说药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492785177?lang=zh_cn&edition=full","pubTime":"2024-12-19 23:25","pubTimestamp":1734621943,"startTime":"0","endTime":"0","summary":"此次获批对公司及子公司未来营业收入具有积极影响。本次检查是美国FDA对尖峰药业受托生产的左乙拉西坦缓释片增加尖峰药业为新生产基地的批准前现场检查。近日，尖峰药业收到了美国FDA签发的现场检查报告，表明美国FDA对尖峰药业的PAI检查已结束，尖峰药业通过了现场检查，有资格进行该产品的生产。双方同意每两年对产品价格进行审查、重新评估及定价，价格将下调22%左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219232705ab84b721&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219232705ab84b721&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600380","BK0188","BK0114","BK0077","603222","BK0251","BK0028","BK0239","BK0201","BK0060","BK0046","300558"],"gpt_icon":0},{"id":"2492114280","title":"贝达药业：控股子公司盐酸恩沙替尼胶囊获美国FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492114280","media":"中国财富通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492114280?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:30","pubTimestamp":1734600654,"startTime":"0","endTime":"0","summary":"中国财富通12月19日 - 贝达药业（300558）公告称，公司控股子公司Xcovery Holdings,\nInc.申报的有关盐酸恩沙替尼胶囊（商品名：Ensacove，简称“恩沙替尼”）“拟用于既往未接受过间变性淋巴瘤激酶（ALK）抑制剂治疗的ALK阳性局部晚期或转移性非小细胞肺癌（NSCLC）成年患者的治疗”（即一线适应症）已获美国FDA批准上市。本次获美国FDA批准上市后，Xcovery即可生产并销售恩沙替尼，此次获批对公司及子公司未来营业收入具有积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=z99QKvcm0YA%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2492192947","title":"贝达药业(300558.SZ)子公司Xcovery盐酸恩沙替尼胶囊获美国FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492192947","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492192947?lang=zh_cn&edition=full","pubTime":"2024-12-19 11:53","pubTimestamp":1734580385,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)公告，在美国食品药品监督管理局(简称“美国FDA”)官网查询到，公司控股子公司Xcovery Holdings, Inc.(简称“Xcovery”)申报的有关盐酸恩沙替尼胶囊(商品名：Ensacove，简称“恩沙替尼”)“拟用于既往未接受过间变性淋巴瘤激酶(ALK)抑制剂治疗的ALK阳性局部晚期或转移性非小细胞肺癌(NSCLC)成年患者的治疗”(即一线适应症)已获美国FDA批准上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"贝达药业(300558.SZ)子公司Xcovery盐酸恩沙替尼胶囊获美国FDA批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2492185338","title":"贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押94.8万股，占总股本0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185338","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492185338?lang=zh_cn&edition=full","pubTime":"2024-12-18 21:23","pubTimestamp":1734528204,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月18日公开信息显示，股东宁波凯铭投资管理合伙企业向山东省国际信托股份有限公司合计质押94.8万股，占总股本0.23%。质押详情见下表：截止本公告日，股东宁波凯铭投资管理合伙企业已累计质押股份5699.12万股，占其持股总数的71.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800038459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2491506886","title":"海通国际：给予贝达药业增持评级，目标价位69.08元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491506886","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491506886?lang=zh_cn&edition=full","pubTime":"2024-12-16 17:35","pubTimestamp":1734341719,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng,Wenxin Yu近期对贝达药业进行研究并发布了研究报告《公司跟踪报告：业绩拐点已至，公司大步迈入创新药放量新周期》，本报告对贝达药业给出增持评级，认为其目标价位为69.08元，当前股价为54.95元，预期上涨幅度为25.71%。利用可比公司估值法，我们给予其2024年57倍PE，对应目标价69.08元，给予“优于大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600024758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"gpt_icon":0},{"id":"2490086938","title":"贝达药业：公司一贯重视现金流管理，通过有效的预算管理、筹资管理等机制保持着健康的财务状况","url":"https://stock-news.laohu8.com/highlight/detail?id=2490086938","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490086938?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:00","pubTimestamp":1733997645,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月12日在投资者关系平台上答复投资者关心的问题。公司一贯重视现金流管理，通过有效的预算管理、筹资管理等机制保持着健康的财务状况。目前，公司已有五款上市药品，营收现金流能够满足日常经营需求与新药开发的持续投入。公司如有重大融资计划，会及时公告披露。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200030678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2488251166","title":"贝达药业(300558.SZ)向171名激励对象授予168.98万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2488251166","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488251166?lang=zh_cn&edition=full","pubTime":"2024-12-04 19:07","pubTimestamp":1733310446,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布公告，公司审议通过了《关于向激励对象授予2023年限制性股票激励计划预留部分限制性股票的议案》，确定以2024年12月4日为预留授予日，以41元/股的授予价格向符合授予条件的171名激励对象授予168.98万股限制性股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2487858276","title":"11月29日贝达药业涨5.05%，圆信永丰兴源灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487858276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487858276?lang=zh_cn&edition=full","pubTime":"2024-11-29 16:16","pubTimestamp":1732868171,"startTime":"0","endTime":"0","summary":"证券之星消息，11月29日贝达药业涨5.05%，收盘报55.35元，换手率2.95%，成交量12.29万手，成交额6.69亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共32家，其中持有数量最多的公募基金为圆信永丰兴源灵活配置混合A。圆信永丰兴源灵活配置混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900023577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2487358275","title":"贝达药业涨5.05%，东海证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2487358275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487358275?lang=zh_cn&edition=full","pubTime":"2024-11-29 16:16","pubTimestamp":1732868164,"startTime":"0","endTime":"0","summary":"今日贝达药业涨5.05%，收盘报55.35元。2024年11月3日，东海证券研究员杜永宏,伍可心发布了对贝达药业的研报《公司简评报告：业绩略超预期，恩沙替尼国际化进展顺利》，该研报对贝达药业给出“买入”评级。研报中预计公司2024-2026年实现营收31.41/39.43/49.17亿元，实现归母净利润5.17/6.81/8.78亿元，对应EPS分别为1.23/1.63/2.10元，对应PE分别为37.31/28.29倍/21.94倍，维持“买入”评级。贝达药业个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900023573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","161027"],"gpt_icon":0},{"id":"2486461398","title":"贝达药业最新公告：甲磺酸贝福替尼一线治疗适应症纳入《国家医保目录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2486461398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486461398?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:20","pubTimestamp":1732785628,"startTime":"0","endTime":"0","summary":"贝达药业公告，公司产品甲磺酸贝福替尼胶囊（赛美纳®）一线治疗适应症纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800029025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2486939856","title":"贝达药业(300558.SZ)甲磺酸贝福替尼一线治疗适应症纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486939856","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486939856?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:18","pubTimestamp":1732785505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)公告，2024年11月28日，根据国家医保局、人力资源社会保障部印发的《关于印发〈国家基本医疗保险、工伤保险和生育保险药品目录(2024年)〉的通知》【医保发〔2024〕33号】，公司产品甲磺酸贝福替尼胶囊(赛美纳®，简称：“贝福替尼”)一线治疗适应症纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》(简称：《国家医保目录》)。贝福替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)，是全新的、拥有自主知识产权的国家1类创新药。本次纳入医保的为贝福替尼一线治疗适应症，于2023年10月获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2486091097","title":"A股创新药板块冲高，葫芦娃涨停，汇宇制药涨超7%，赛隆药业、贝达药业、艾力斯等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2486091097","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486091097?lang=zh_cn&edition=full","pubTime":"2024-11-26 09:47","pubTimestamp":1732585635,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688553","002898","BK1161","399300","06978","605199","159992","BK0060","BK0239","BK1574","300558","159982","688578"],"gpt_icon":0},{"id":"2486709868","title":"来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709868","media":"活报告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486709868?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:14","pubTimestamp":1732529640,"startTime":"0","endTime":"0","summary":"LiveReport获悉，来自武汉的翰思艾泰生物医药科技（武汉）股份有限公司于2024年11月24日在港交所递交上市申请，拟香港主板上市，这是该公司第1次递交上市申请，独家保荐人为工银国际。截至最后实际可行日期，正在澳大利亚启动用于治疗晚期实体瘤恶性肿瘤的I/IIa期临床研究，并取得国家药监局就其在中国的临床研究的受理通知。截至2024年6月30日，公司账上现金1.5亿元。预计2031年全球肿瘤免疫疗法市场将占全球肿瘤药物市场份额的50.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2024-11-25/doc-incxhqmk8163822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1820825898.SGD","BK0077","BK1583","300347","03347","BK1576","BK0174","BK1141","LU1146622755.USD","BK0216","300558","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2486372701","title":"翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2486372701","media":"瑞恩资本Ryanbe...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486372701?lang=zh_cn&edition=full","pubTime":"2024-11-25 13:52","pubTimestamp":1732513920,"startTime":"0","endTime":"0","summary":"2024年11月24日，来自湖北武汉的翰思艾泰生物科技(武汉)股份有限公司Hanx Biopharmaceuticals Co., Ltd.在港交所递交招股书，拟香港主板IPO上市。翰思艾泰的核心产品HX009是一种自主研发的PD-1/SIRPα双功能抗体融合蛋白，目前已在澳大利亚及中国完成HX009的I期临床试验。翰思艾泰已完成根据国家药监局批准对HX301进行的I期临床研究，并计划开展HX301与替莫唑胺联用治疗脑胶质母细胞瘤的II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-25/doc-incxhcvq8260278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","LU1820825898.SGD","600133","HK0000306701.USD","BK0277","01548","BK0060","BK0077","300558","BK0086","HK0000306685.HKD","BK0028","LU1146622755.USD","BK0075","HK0000320223.HKD","BK0174","HK0000320264.USD","BK0239","BK0102","BK1576","BK1583","300347","BK1141"],"gpt_icon":0},{"id":"2486495737","title":"贝达药业（300558）11月22日主力资金净卖出3327.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486495737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486495737?lang=zh_cn&edition=full","pubTime":"2024-11-25 09:19","pubTimestamp":1732497589,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月22日收盘，贝达药业报收于49.36元，下跌7.04%，换手率2.57%，成交量10.74万手，成交额5.48亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入6348.22万元，融资偿还5378.76万元，融资净买入969.45万元。贝达药业主营业务：本公司是一家由海归博士创办的,以自主知识产权创新药物研究与开发为核心,集研发、生产、市场营销于一体的国家级高新技术企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500002253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2485423635","title":"贝达药业(300558.SZ)：盐酸恩沙替尼胶囊临床中心通过美国FDA现场核查","url":"https://stock-news.laohu8.com/highlight/detail?id=2485423635","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485423635?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:50","pubTimestamp":1732265456,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)发布公告，关于盐酸恩沙替尼胶囊临床中心通过美国FDA...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2485323303","title":"11月22日贝达药业跌7.04%，圆信永丰兴源灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485323303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485323303?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:31","pubTimestamp":1732264289,"startTime":"0","endTime":"0","summary":"证券之星消息，11月22日贝达药业跌7.04%，收盘报49.36元，换手率2.57%，成交量10.74万手，成交额5.48亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共32家，其中持有数量最多的公募基金为圆信永丰兴源灵活配置混合A。圆信永丰兴源灵活配置混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200026117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2485043871","title":"贝达药业（300558）11月20日主力资金净买入2097.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485043871","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485043871?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:11","pubTimestamp":1732151468,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月20日收盘，贝达药业报收于52.81元，上涨12.48%，换手率4.99%，成交量20.8万手，成交额10.84亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入8279.17万元，融资偿还1.15亿元，融资净偿还3214.42万元。贝达药业主营业务：本公司是一家由海归博士创办的,以自主知识产权创新药物研究与开发为核心,集研发、生产、市场营销于一体的国家级高新技术企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100007084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2484162524","title":"贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484162524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484162524?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:30","pubTimestamp":1732095003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业 公告，今日，公司收到国家药品监督管理局签发的《受理通知书》，公司申报的BPI-452080片药物临床试验申请已获得NMPA受理。据悉，BPI-452080是一个由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、口服的小分子HIF-2α抑制剂，拟用于vonHippel-Lindau综合征相关肿瘤和实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1583","BK1141","03347","BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2484678341","title":"贝达药业最新公告：BPI-452080片药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484678341","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484678341?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:29","pubTimestamp":1732094984,"startTime":"0","endTime":"0","summary":"贝达药业公告，公司收到NMPA签发的《受理通知书》，公司申报的BPI-452080片药物临床试验申请已获得NMPA受理。BPI-452080片是一种创新、口服的小分子HIF-2α抑制剂，拟用于VHL综合征相关肿瘤和实体瘤。该药物属于“境内外均未上市的创新药”，注册分类为化学药品1类。临床试验申请获得受理后，公司可以按照提交的方案开展临床试验，但新药临床试验申请审批结果及时间具有不确定性，投资者需注意防范投资风险。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000031357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1141","300558","03347","BK0239","BK1576","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","stockEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.1608},{"period":"3month","weight":0.5043},{"period":"6month","weight":0.5228},{"period":"1year","weight":0.0508},{"period":"ytd","weight":0.062}],"companyName":"贝达药业股份有限公司","boardCode":"AI0027","perCapita":"12790股","boardName":"医药制造业","registeredCapital":"41848万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖（两次）、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。","serverTime":1734683903055,"listedPrice":17.57,"stockholders":"32616人(较上一季度减少7.16%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}